The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Expansion In Market Value Is Forecasted For The Biologics Manufacturing Market Between 2026 And 2030?
The biologics manufacturing market size has seen exponential expansion in recent years. It is projected to increase from $42.04 billion in 2025 to $50.69 billion in 2026, achieving a compound annual growth rate (CAGR) of 20.6%. The historical growth can be attributed to the expansion of recombinant protein therapeutics, the early adoption of mammalian cell culture systems, increased capacity in vaccine manufacturing, the growing trend of outsourcing biologics production, and advancements in purification technologies.
The biologics manufacturing market is projected to experience rapid expansion over the coming years. By 2030, this market is anticipated to reach a valuation of $106.08 billion, exhibiting a compound annual growth rate (CAGR) of 20.3%. This projected growth during the forecast period is primarily driven by factors such as the increasing need for personalized biologics, higher investments in adaptable manufacturing platforms, the broadening scope of biosimilar development, the wider integration of digital bioprocessing solutions, and an emphasis on economical, large-scale production methods. Key trends anticipated for the forecast timeframe involve the increasing use of single-use bioprocessing systems, the expanding implementation of continuous biomanufacturing, a heightened demand for producing high volumes of monoclonal antibodies, the development of more modular biologics facilities, and improved incorporation of advanced process control.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30212&type=smp
Which Drivers Are Supporting The Biologics Manufacturing Market Growth?
The expanding occurrence of chronic illnesses is anticipated to boost the biologics manufacturing market’s growth in the future. These are long-term health issues that progress slowly and require ongoing medical attention. A major factor contributing to the increasing incidence of chronic diseases is sedentary lifestyles, where extended periods of sitting and minimal physical activity elevate the risk of conditions like heart problems and diabetes. Biologics production improves the management of chronic diseases by creating specific therapies, which are effective for ailments such as diabetes, cancer, and autoimmune disorders. This also lessens the overall disease impact by delivering reliable, high-quality biologic medications, leading to better patient results and more efficient treatments. As an illustration, in June 2024, the National Health Service, a UK government body, reported that 3,615,330 people registered with a GP were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with raised blood sugar levels, not high enough for a diabetes diagnosis) in 2023, representing an 18% rise from 3,065,825 cases in 2022. Consequently, the increasing prevalence of chronic diseases is a key driver for the biologics manufacturing market’s expansion.
How Are Segments Identified Within The Biologics Manufacturing Market Segment Framework?
The biologics manufacturing market covered in this report is segmented –
1) By Mode of Manufacturing: Contract Manufacturing, In-House Manufacturing
2) By Modality: Monoclonal Antibodies (mAbs), Biosimilar And Recombinant Proteins, Vaccines (recombinant/mRNA/Viral), Cell And Gene Therapies, Ribonucleic Acid-Based Therapeutics
3) By Disease Indication: Oncology, Autoimmune Disorders, Infectious Diseases, Neurological Disorders, Other Disease Indications
Subsegments:
1) By Contract Manufacturing: Mammalian Cell-Based Production, Microbial Fermentation Production, Cell-Free Protein Synthesis, Hybrid Manufacturing Systems
2) By In-House Manufacturing: Mammalian Cell Culture Production, Microbial Expression Systems, Continuous Bioprocessing, Single-Use Technology Production
Which Trends Are Influencing Demand In The Biologics Manufacturing Market?
Leading companies within the biologics manufacturing market are concentrating on creating sophisticated solutions, including integrated biologics contract development and manufacturing organization platforms. This focus aims to improve comprehensive biologics development, boost production efficiency, and strengthen supply chain integration across various therapeutic areas. An integrated biologics CDMO platform is defined as an extensive framework that unifies biologics development, production, and supply services into one cohesive system. As an illustration, Catalent Inc., a US-based contract development and manufacturing firm, expanded its OneBio Suite in June 2023 to offer integrated development, manufacturing, and supply services across diverse biologic modalities. The upgraded OneBio Suite now provides a fully integrated biologics CDMO platform designed to support antibodies, cell and gene therapies, and mRNA-based products. This platform delivers complete services, from initial development through to fill-finish and packaging, under a single contract and unified project management, facilitating quicker development schedules, enhanced scalability, and smooth global supply integration.
Who Are The Companies Competing Within The Biologics Manufacturing Market?
Major companies operating in the biologics manufacturing market are Johnson & Johnson, F. Hoffmann La-Roche Ltd., Pfizer Inc, AbbVie Inc., Eli Lilly and Company, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., LG Life Sciences Ltd., Novo Nordisk A/S, Amgen Inc., FUJIFILM Holdings Corporation, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Lonza Group Ltd., Intas Pharmaceuticals Ltd., Samsung Biologics Co. Ltd., Fareva SA, Celltrion Inc., Evotec SE
Get The Full Biologics Manufacturing Market Report:
https://www.thebusinessresearchcompany.com/report/global-biologics-manufacturing-market-report
Where Is The Biologics Manufacturing Market Most Concentrated Geographically?
North America was the largest region in the biologics manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Biologics Manufacturing Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/global-biologics-manufacturing-market-report
Browse Through More Reports Similar to the Global Biologics Manufacturing Market 2026, By The Business Research Company
Biologics Contract Development Market Report 2026
Biologics Outsourcing Market Report 2026
https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report
Biologics Testing Market Report 2026
https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model